Loss of heterozygosity

Caris Life Sciences Introduces the Caris Assure™ Liquid Biopsy Assay at ASCO 2022

Retrieved on: 
Friday, June 3, 2022
Loss of heterozygosity, Exome, Indeterminate, Research, Society, Liquid biopsy, Transcriptome, Neoplasm, MBA, Weld quality assurance, Plague, Artificial intelligence, CHIP, RNA, TMB, CEO, Disease, ASCO, CFRNA, WES, Blood, Annual general meeting, Gene, Physician, MSI, Nucleic acid thermodynamics, American Society of Clinical Oncology, Patient, DNA, American Securities, Microsatellite instability, Diagnosis, Twitter, WTS, Industry, Drug development, LOH, Cancer, Protein, Medical imaging, Dentistry, Medical device

CHICAGO, June 3, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today introduced its Caris Assure™ liquid biopsy assay at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Booth #22081).

Key Points: 
  • Caris Assure is the most powerful liquid biopsy assay ever developed, providing whole exome and whole transcriptome sequencing (WES/WTS) assessing somatic tumor, somatic CHIP and germline alterations
    CHICAGO, June 3, 2022 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today introduced its Caris Assure liquid biopsy assay at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Booth #22081).
  • "Caris Assure establishes a new standard for liquid biopsy testing," said David D. Halbert , Chairman, Founder and CEO of Caris Life Sciences.
  • With Caris Assure, we have created the most extensive sequencing assay available to ensure we leave no stone unturned in properly guiding treatment selection and ongoing cancer care management."
  • This unique assay includes characterization of somatic tumor alterations, somatic Clonal Hematopoiesis of Indeterminate Potential (CHIP) alterations and identification of incidental germline findings.

New Nature Study Uses Mission Bio's Tapestri Platform for Single-nuclei Sequencing of Solid Tissue

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Biology, Mutation, Evolutionary biology, Genetics, DNA, Loss of heterozygosity, Somatic mutation, Omics, Multiomics, Cancer

The study is a milestone for the disease area, demonstrating a cancer-like paradigm where multiple somatic mutations accumulate in the same cells.

Key Points: 
  • The study is a milestone for the disease area, demonstrating a cancer-like paradigm where multiple somatic mutations accumulate in the same cells.
  • We are excited to apply the Tapestri Platform to other rare diseases and archived tissue and to use it to elucidate other genomic aberrations, like loss of heterozygosity.
  • "The findings of this Nature study helpvalidate our belief that enabling DNA analysis at the single-nuclei level out of solid tissue is critical to the understanding of many diseases beyond cancer.
  • Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously, from the same sample at single-cell resolution.

Tempus Announces Companion Diagnostic Collaboration With A2 Biotherapeutics

Retrieved on: 
Wednesday, January 13, 2021
Data management, Health, Technology, Software, Pharmaceutical, Hardware, Biotechnology, Branches of biology, Biology, Medical tests, CDX, Loss of heterozygosity, Companion diagnostic

Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH).

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH).
  • A2, a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, is collaborating with Tempus to validate its leading xT sequencing assay to specifically identify patients with the LOH genetic alteration.
  • We believe that our proprietary platform is ideal for companion diagnostic collaborations, said Michael Yasiejko, Chief Commercial Officer.
  • We identified Tempus as the ideal collaborator for this CDx given its smart genomic testing platform and the scope of its dataset, said William Go, MD, PhD, Senior Vice President and Head of Development at A2 Biotherapeutics.